January 22, 2018
11 am to 12 pm EST
Champions Oncology has pioneered an advanced PDX platform for modeling hematology oncology malignancies, including AML and ALL. The platform consists of leukapheresis AML and ALL clinical patient samples that are characterized for the ability to engraft
P1 study mice. Champions has also established a resource for modeling defined patient populations as they progress co-clinically by collecting blasts from patients as they progress in the clinic. Both approaches represent advantageous approaches,
with the leukapheresis resource allowing for modeling large numbers of study mice across an established panel of patient samples and the co-clinical resource providing for modeling defined patient cohorts co-clinically.
- Review the growing datasets supporting the Champions Oncology’s hematology AML and ALL modeling platform in P1 mice
- Describe AML and ALL leukapheresis PDX modeling
- Describe AML co-clinical PDX modeling platform
Neal Goodwin, Ph.D.
Vice President Corporate Research & Development
Neal Goodwin, Ph.D. serves as Vice President, Corporate Research & Development for Champions Oncology (NASDAQ: CSBR). His responsibilities include development of a patient derived tumor graft pharmacology portfolio for oncology drug development
solutions. He previously served as the Director, Research and Development and the founding Program Director of JAX Cancer Services where he established a patient derived tumor biology program in collaboration with over 20 cancer centers. Dr. Goodwin
is co-founder and a former Chief Scientific Officer of ProNAi Therapeutics (NASDAQ: DNAI), and he has served as a senior research scientist in genomic technologies at Pharmacia. Dr. Goodwin received a Ph.D in Microbiology from the University of
Montana and served a postdoctoral fellowship in functional genomics at The Jackson Laboratory with John Schimenti (now at Cornell).